Login
欢迎浏览恩派尔生物资料网
我要投稿 请登录 免费注册 安全退出

您现在的位置是: 首页 > 实验方法 > 生物化学

生物化学

Antibody Humanization by CDR Grafting

2025-03-29 生物化学 加入收藏
The goal of antibody humanization is to engineer a monoclonal antibody (MAb) rai

The goal of antibody humanization is to engineer a monoclonal antibody (MAb) raised in a nonhuman species into one that is less immunogenic when administered to humans. The development of this technology had transformed the stagnant state of antibody therapeutics in the 1980s, when the major obstacle was the human anti-murine antibody (HAMA) response (1 , 2 ). The HAMA response occurred in up to 50% of patients upon the administration of murine hybridoma-derived antibodies (3 ) and severely compromised the safety, efficacy, and biological half-life of these reagents. In addition, murine antibody constant regions are inefficient in directing suitable human immune effector functions for therapeutic effects. Efforts to produce human antibodies by hybridoma technology (4 ) and Epstein-Barr virus (EBV)-mediated B-lymphocyte transformation (5 ) have met with limited success, but their widespread application is hampered by the lack of robust human hybridoma fusion partners and the instability of EBV-transformed clones, respectively (see ref. 6 –8 for review). Consequently, humanization technology was well-placed to exploit the plethora of murine MAbs against a variety of disease targets and turn them into effective clinical reagents.

文章底部广告位

文章评论

加载中~